1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress)
Publication
, Conference
Park, H; Bekaii-Saab, T; Kim, S; Kamath, S; Pishvaian, M; Ford, J; Zhen, D; Mayor, J; Lux, C; Tan, Q; Strickler, J
Published in: Annals of Oncology
September 2021
Duke Scholars
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S1073 / S1074
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Park, H., Bekaii-Saab, T., Kim, S., Kamath, S., Pishvaian, M., Ford, J., … Strickler, J. (2021). 1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress). In Annals of Oncology (Vol. 32, pp. S1073–S1074). Elsevier BV. https://doi.org/10.1016/j.annonc.2021.08.1546
Park, H., T. Bekaii-Saab, S. Kim, S. Kamath, M. Pishvaian, J. Ford, D. Zhen, et al. “1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress).” In Annals of Oncology, 32:S1073–74. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.1546.
Park H, Bekaii-Saab T, Kim S, Kamath S, Pishvaian M, Ford J, et al. 1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress). In: Annals of Oncology. Elsevier BV; 2021. p. S1073–4.
Park, H., et al. “1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress).” Annals of Oncology, vol. 32, Elsevier BV, 2021, pp. S1073–74. Crossref, doi:10.1016/j.annonc.2021.08.1546.
Park H, Bekaii-Saab T, Kim S, Kamath S, Pishvaian M, Ford J, Zhen D, Mayor J, Lux C, Tan Q, Strickler J. 1437TiP Phase Ib/II, open label, dose escalation and expansion trial of tucatinib in combination with trastuzumab and oxaliplatin-based chemotherapy in patients with unresectable or metastatic HER2+ gastrointestinal cancers (trial in Progress). Annals of Oncology. Elsevier BV; 2021. p. S1073–S1074.
Published In
Annals of Oncology
DOI
ISSN
0923-7534
Publication Date
September 2021
Volume
32
Start / End Page
S1073 / S1074
Publisher
Elsevier BV
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis